Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1625 1626 1628 1657 1672
This examiner grants 73% of resolved cases
Janet L. Coppins is an examiner in Tech Center 1600 and Art Unit 1621. She has reached a final disposition in 933 resolved cases. The allowance rate for these cases is 72.6%. The median days to allowance is 848 days. This 848-day period provides a specific timeline for the duration of the examination process in her portfolio.
The interview lift for this examiner is 26.1%. This metric indicates that conducting an interview is associated with an increase in the probability of an allowance compared to cases without such engagement. With 933 resolved cases, the 72.6% allowance rate represents the frequency of grants in her portfolio. Practitioners in Tech Center 1600 can use the 26.1% lift to assess the impact of direct communication. The 848-day median pendency is a factor for managing expectations in Art Unit 1621.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17712527 | PHARMACEUTICAL COMPOSITION AND KIT CONTAINING NOVEL PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM beta-LACTAMASE INHIBITORY COMPOUND AND ANTIBACTERIAL COMPOUND OR SALTS THEREOF | Final Rejection | FUJIFILM Corporation |
| 18438385 | BIFUNCTIONAL CHEMICAL EPIGENENTIC MODIFIERS AND METHODS OF USE | Final Rejection | The University of North Carolina at Chapel Hill |
| 18501175 | AHR AGONISTS | Non-Final OA | Eli Lilly and Company |
| 18685357 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 17252771 | COMPOSITION COMPRISING FLT3 INHIBITOR AS EFFECTIVE INGREDIENT FOR INHIBITING DRUG RESISTANCE IN CHRONIC MYELOGENOUS LEUKEMIA | Final Rejection | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18608354 | COMPOSITIONS AND METHODS FOR TREATING TISSUE INJURY | Final Rejection | CASE WESTERN RESERVE UNIVERSITY |
| 18428639 | Methods for Restoring Sensitivity to TTFields in TTFields-Resistant Cancer Cells with PTGER3 Inhibitors | Final Rejection | Novocure GmbH |
| 17432158 | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD FOR TREATING FGFR1 VARIANT-POSITIVE BRAIN TUMOR | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18570727 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | Non-Final OA | Janssen Pharmaceutica NV |
| 17659274 | TREATING NEURAL DISEASE WITH TYROSINE KINASE INHIBITORS | Final Rejection | GEORGETOWN UNIVERSITY |
| 17059761 | COMPOSITIONS AND METHODS FOR OPIOID OVERDOSE RESCUE | Final Rejection | Purdue Pharma L.P. |
| 17253828 | NOVEL FORMULATIONS COMPRISING KETAMINE | Non-Final OA | Neurocentrx Pharma Ltd. |
| 18099654 | ANIMAL STERILIZATION BY ESTROGENIC COMPOUNDS | Non-Final OA | Insigna Inc. |
| 16498813 | STATIN FOR PREVENTION/REDUCTION OF ISCHEMIA-RELATED DAMAGE | Final Rejection | Gendiag, S.L. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy